|
EP1127882A1
(en)
*
|
2000-01-25 |
2001-08-29 |
Pfizer Products Inc. |
Tetrazole compounds as thyroid receptor ligands
|
|
US6664291B2
(en)
|
2000-03-31 |
2003-12-16 |
Pfizer, Inc. |
Malonamic acids and derivatives thereof as thyroid receptor ligands
|
|
FI107018B
(fi)
*
|
2000-04-06 |
2001-05-31 |
Ipsat Therapies Oy |
Dermatologinen käyttö ja valmiste
|
|
US6395784B1
(en)
*
|
2000-06-07 |
2002-05-28 |
Bristol-Myers Squibb Company |
Benzamide ligands for the thyroid receptor
|
|
DE10038007A1
(de)
*
|
2000-08-04 |
2002-02-14 |
Bayer Ag |
Neue Amino-und Amido-Diphenylether für Arzneimittel
|
|
US7163918B2
(en)
|
2000-08-22 |
2007-01-16 |
New River Pharmaceuticals Inc. |
Iodothyronine compositions
|
|
GB0029100D0
(en)
*
|
2000-11-29 |
2001-01-10 |
Karobio Ab |
Compounds active at the glucocorticoid receptor
|
|
WO2002051805A1
(de)
*
|
2000-12-27 |
2002-07-04 |
Bayer Aktiengesellschaft |
Indol-derivate
|
|
US7504435B2
(en)
|
2001-01-31 |
2009-03-17 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Method for stimulating weight loss and/or for lowering triglycerides in patients
|
|
EP1358175A2
(en)
|
2001-02-08 |
2003-11-05 |
Karo Bio Ab |
Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands
|
|
US6777442B2
(en)
|
2001-03-12 |
2004-08-17 |
Bayer Aktiengesellschaft |
Diphenyl derivatives
|
|
DE10122443A1
(de)
*
|
2001-05-09 |
2002-11-14 |
Bayer Ag |
Amido-Diphenyl-Derivate
|
|
EP1499578A2
(en)
*
|
2001-08-24 |
2005-01-26 |
Karo Bio Ab |
Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
|
|
GB0120691D0
(en)
*
|
2001-08-24 |
2001-10-17 |
Karobio Ab |
Novel Compounds
|
|
DE60208132T2
(de)
|
2001-09-26 |
2006-07-20 |
Pfizer Products Inc., Groton |
Indolcaroboxylsäure als Thyroidrezeptor-Liganden
|
|
US7230031B2
(en)
|
2002-01-30 |
2007-06-12 |
Kissei Pharmaceutical Co., Ltd. |
Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
|
|
GB0208384D0
(en)
*
|
2002-04-11 |
2002-05-22 |
Karobio Ab |
Novel compounds
|
|
GB0215978D0
(en)
*
|
2002-07-10 |
2002-08-21 |
Karobio Ab |
Novel compounds
|
|
KR101025633B1
(ko)
*
|
2002-09-19 |
2011-03-30 |
일라이 릴리 앤드 캄파니 |
오피오이드 수용체 안타고니스트로서의 디아릴 에테르
|
|
EP1477475A1
(en)
*
|
2003-05-16 |
2004-11-17 |
Procorde GmbH |
Compounds for use as a medicine increasing the contractility of a heart, a heart muscle or cells of a heart muscle
|
|
ITRM20030363A1
(it)
*
|
2003-07-24 |
2005-01-25 |
Fernando Goglia |
Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
|
|
US7767828B2
(en)
*
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
|
US7317109B2
(en)
*
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
|
US7576121B2
(en)
*
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
|
NZ547752A
(en)
|
2003-11-12 |
2009-12-24 |
Phenomix Corp |
Heterocyclic boronic acid compounds for inhibiting dipeptidyl peptidase-IV
|
|
CN1882327A
(zh)
|
2003-11-19 |
2006-12-20 |
症变治疗公司 |
含磷的新的拟甲状腺素药
|
|
WO2006128058A2
(en)
|
2005-05-26 |
2006-11-30 |
Metabasis Therapeutics, Inc. |
Thyromimetics for the treatment of fatty liver diseases
|
|
US7795448B2
(en)
|
2004-05-06 |
2010-09-14 |
Cytokinetics, Incorporated |
Imidazoyl-benzamide anti-cancer agents
|
|
US7504413B2
(en)
|
2004-05-06 |
2009-03-17 |
Cytokinetics, Inc. |
N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases
|
|
US7618981B2
(en)
|
2004-05-06 |
2009-11-17 |
Cytokinetics, Inc. |
Imidazopyridinyl-benzamide anti-cancer agents
|
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
|
US7317024B2
(en)
|
2005-01-13 |
2008-01-08 |
Bristol-Myers Squibb Co. |
Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
|
EP2527337A1
(en)
|
2005-04-14 |
2012-11-28 |
Bristol-Myers Squibb Company |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
|
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
|
US7825139B2
(en)
*
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
|
US7452892B2
(en)
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
|
US7632837B2
(en)
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
|
US7629342B2
(en)
|
2005-06-17 |
2009-12-08 |
Bristol-Myers Squibb Company |
Azabicyclic heterocycles as cannabinoid receptor modulators
|
|
US7317012B2
(en)
|
2005-06-17 |
2008-01-08 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoind-1 receptor modulators
|
|
TW200726765A
(en)
|
2005-06-17 |
2007-07-16 |
Bristol Myers Squibb Co |
Triazolopyridine cannabinoid receptor 1 antagonists
|
|
CA2615991C
(en)
*
|
2005-07-19 |
2011-02-08 |
Daiichi Sankyo Company, Limited |
Substituted propanamide derivative and pharmaceutical composition comprising the same
|
|
KR20080033524A
(ko)
*
|
2005-08-10 |
2008-04-16 |
다케다 야쿠힌 고교 가부시키가이샤 |
당뇨병 치료제
|
|
US7795436B2
(en)
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
|
US8618115B2
(en)
|
2005-10-26 |
2013-12-31 |
Bristol-Myers Squibb Company |
Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
|
|
EP1943215A2
(en)
|
2005-10-31 |
2008-07-16 |
Brystol-Myers Squibb Company |
Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
|
|
TW200738621A
(en)
*
|
2005-11-28 |
2007-10-16 |
Astrazeneca Ab |
Chemical process
|
|
US7553836B2
(en)
|
2006-02-06 |
2009-06-30 |
Bristol-Myers Squibb Company |
Melanin concentrating hormone receptor-1 antagonists
|
|
MX2008013238A
(es)
|
2006-04-12 |
2008-10-21 |
Merck & Co Inc |
Antagonistas de los canales de calcio de tipo t de piridil amida.
|
|
WO2007120083A1
(en)
*
|
2006-04-13 |
2007-10-25 |
Astrazeneca Ab |
The use of carboxamide derivatives in the manufacture of a medicament for the treatment of inflammatory, allergic and dermatological conditions
|
|
FR2900404B1
(fr)
*
|
2006-04-27 |
2008-07-18 |
Sod Conseils Rech Applic |
Nouveaux derives d'imidazoles, leur preparation et leur utilisation en tant que medicament
|
|
WO2007132475A1
(en)
*
|
2006-05-15 |
2007-11-22 |
Cadila Healthcare Limited |
Selective tr-beta 1 agonist
|
|
US20100022457A1
(en)
|
2006-05-26 |
2010-01-28 |
Bristol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
|
US7727978B2
(en)
|
2006-08-24 |
2010-06-01 |
Bristol-Myers Squibb Company |
Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
|
EP2089355A2
(en)
|
2006-11-01 |
2009-08-19 |
Brystol-Myers Squibb Company |
Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof
|
|
RU2395489C2
(ru)
*
|
2006-11-01 |
2010-07-27 |
Институт элементоорганических соединений имени А.Н.Несмеянова Российской академии наук (ИНЭОС РАН) |
[f-18] меченная l-глютаминовая кислота, [f-18] меченный l-глютамин, их производные и их применение, а также способ их получения
|
|
US8198311B2
(en)
|
2006-11-01 |
2012-06-12 |
Bristol-Myers Squibb Company |
Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
|
CN101674801A
(zh)
*
|
2007-01-31 |
2010-03-17 |
西巴控股公司 |
阳离子染料
|
|
WO2008106213A1
(en)
|
2007-02-27 |
2008-09-04 |
Titan Pharmaceuticals, Inc. |
Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome.
|
|
AR065809A1
(es)
|
2007-03-22 |
2009-07-01 |
Bristol Myers Squibb Co |
Formulaciones farmaceuticas que contienen un inhibidor sglt2
|
|
US8546394B2
(en)
|
2007-04-17 |
2013-10-01 |
Bristol-Myers Squibb Company |
Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors
|
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
|
US20090011994A1
(en)
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
|
CN101808995A
(zh)
|
2007-07-27 |
2010-08-18 |
百时美施贵宝公司 |
新颖的葡糖激酶激活剂及其使用方法
|
|
RU2443699C2
(ru)
*
|
2007-09-20 |
2012-02-27 |
Айрм Ллк |
Соединения и композиции в качестве модуляторов активности gpr119
|
|
CN101910133A
(zh)
*
|
2007-10-24 |
2010-12-08 |
默沙东公司 |
杂环苯基酰胺t-型钙通道拮抗剂
|
|
ES2448839T3
(es)
|
2007-11-01 |
2014-03-17 |
Bristol-Myers Squibb Company |
Compuestos no esteroideos útiles como moderadores de la actividad del receptor de glucocorticoides AP-1 y/o NF-kappa b y uso de los mismos
|
|
GB0725214D0
(en)
*
|
2007-12-24 |
2008-02-06 |
Karobio Ab |
Pharmaceutical compounds
|
|
PE20091928A1
(es)
|
2008-05-29 |
2009-12-31 |
Bristol Myers Squibb Co |
Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
|
|
CA2741517A1
(en)
*
|
2008-10-27 |
2010-05-06 |
Cadila Healthcare Limited |
Thyroid receptor ligands
|
|
EP2356979B1
(en)
|
2008-11-19 |
2017-10-25 |
Pola Chemical Industries Inc. |
Anti-wrinkle agents
|
|
WO2010086878A2
(en)
|
2009-01-09 |
2010-08-05 |
Cadila Healthcare Limited |
Thyroid receptor modulators
|
|
SG174504A1
(en)
|
2009-03-27 |
2011-10-28 |
Bristol Myers Squibb Co |
Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
|
|
TWI534144B
(zh)
*
|
2009-04-20 |
2016-05-21 |
田邊三菱製藥股份有限公司 |
甲狀腺荷爾蒙β受體作動藥
|
|
JP5784623B2
(ja)
|
2009-11-13 |
2015-09-24 |
アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ |
速放性錠剤製剤
|
|
EP3315124B1
(en)
|
2009-11-13 |
2021-01-06 |
Astrazeneca AB |
Bilayer tablet formulations
|
|
CN102711738A
(zh)
|
2009-11-13 |
2012-10-03 |
百时美施贵宝公司 |
质量得以减小的二甲双胍制剂
|
|
WO2011103126A1
(en)
*
|
2010-02-17 |
2011-08-25 |
Ampla Pharmaceuticals Inc. |
Treatment of metabolic syndrome with piperidine amides
|
|
US8592396B2
(en)
|
2010-04-14 |
2013-11-26 |
Bristol-Myers Squibb Company |
Glucokinase activators and methods of using same
|
|
AR081626A1
(es)
|
2010-04-23 |
2012-10-10 |
Cytokinetics Inc |
Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
|
|
AR081331A1
(es)
|
2010-04-23 |
2012-08-08 |
Cytokinetics Inc |
Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
|
|
US9133123B2
(en)
|
2010-04-23 |
2015-09-15 |
Cytokinetics, Inc. |
Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
|
|
WO2012004743A1
(en)
|
2010-07-09 |
2012-01-12 |
Pfizer Limited |
Benzenesulfonamides useful as sodium channel inhibitors
|
|
EP2593433B1
(en)
|
2010-07-12 |
2014-11-26 |
Pfizer Limited |
N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
|
|
JP2013532185A
(ja)
|
2010-07-12 |
2013-08-15 |
ファイザー・リミテッド |
化合物
|
|
JP2013532184A
(ja)
|
2010-07-12 |
2013-08-15 |
ファイザー・リミテッド |
電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体
|
|
US9102621B2
(en)
|
2010-07-12 |
2015-08-11 |
Pfizer Limited |
Acyl sulfonamide compounds
|
|
ES2532357T3
(es)
|
2010-07-12 |
2015-03-26 |
Pfizer Limited |
Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor
|
|
JP6014155B2
(ja)
|
2011-10-31 |
2016-10-25 |
ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． |
ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
|
|
RU2014121984A
(ru)
|
2011-10-31 |
2015-12-10 |
Ксенон Фармасьютикалз Инк. |
Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
|
|
CA2857603C
(en)
|
2011-12-15 |
2016-08-02 |
Pfizer Limited |
Sulfonamide derivatives
|
|
US20150291514A1
(en)
*
|
2012-01-04 |
2015-10-15 |
Pfizer Limted |
N-Aminosulfonyl Benzamides
|
|
CN104718188B
(zh)
|
2012-05-22 |
2018-08-21 |
基因泰克公司 |
N-取代的苯甲酰胺类及其在治疗疼痛中的用途
|
|
CN102718718B
(zh)
*
|
2012-05-31 |
2014-09-24 |
绍兴文理学院 |
一种3,5-二溴-4-（5-苯并咪唑氧基）苯乙酸的制备方法
|
|
KR101663436B1
(ko)
*
|
2012-07-06 |
2016-10-06 |
제넨테크, 인크. |
N-치환된 벤즈아미드 및 이의 사용 방법
|
|
EP2892896B1
(en)
|
2012-09-05 |
2016-06-29 |
Bristol-Myers Squibb Company |
Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
|
|
EP2892897A1
(en)
|
2012-09-05 |
2015-07-15 |
Bristol-Myers Squibb Company |
Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
|
|
RU2015143906A
(ru)
|
2013-03-14 |
2017-04-18 |
Дженентек, Инк. |
Замещенные триазолопиридины и способы их применения
|
|
BR112015023397A2
(pt)
|
2013-03-15 |
2017-07-18 |
Genentech Inc |
benzoxazois substituídos e métodos de uso dos mesmos
|
|
US9593113B2
(en)
|
2013-08-22 |
2017-03-14 |
Bristol-Myers Squibb Company |
Imide and acylurea derivatives as modulators of the glucocorticoid receptor
|
|
WO2015078374A1
(en)
|
2013-11-27 |
2015-06-04 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
|
CN103709094B
(zh)
*
|
2014-01-07 |
2016-04-06 |
厦门大学 |
4-苯氧基苯甲酰胺类化合物及其制备方法和应用
|
|
JP2017525677A
(ja)
|
2014-07-07 |
2017-09-07 |
ジェネンテック， インコーポレイテッド |
治療用化合物及びその使用方法
|
|
HK1252567A1
(zh)
|
2015-05-22 |
2019-05-31 |
基因泰克公司 |
被取代的苯甲酰胺和其使用方法
|
|
JP2018526371A
(ja)
|
2015-08-27 |
2018-09-13 |
ジェネンテック， インコーポレイテッド |
治療化合物及びその使用方法
|
|
CA2999769A1
(en)
|
2015-09-28 |
2017-04-06 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
|
EP3380466A1
(en)
|
2015-11-25 |
2018-10-03 |
Genentech, Inc. |
Substituted benzamides useful as sodium channel blockers
|
|
EP3436432B1
(en)
|
2016-03-30 |
2021-01-27 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
|
US11447460B2
(en)
|
2016-04-18 |
2022-09-20 |
Novartis Ag |
Compounds and compositions for treating conditions associated with NLRP activity
|
|
US11325886B2
(en)
|
2016-08-12 |
2022-05-10 |
Oregon Health & Science University |
Amide compounds, pharmaceutical compositions thereof, and methods of using the same
|
|
PE20190980A1
(es)
|
2016-10-17 |
2019-07-09 |
Genentech Inc |
Compuestos terapeuticos y metodos para utilizarlos
|
|
CA3044059A1
(en)
|
2016-11-21 |
2018-05-24 |
Viking Therapeutics, Inc. |
Method of treating glycogen storage disease
|
|
CN106588690B
(zh)
*
|
2016-12-19 |
2019-06-04 |
广西中医药大学 |
毛鸡骨草甲素Abrusamide的制备方法
|
|
JP2020511511A
(ja)
|
2017-03-24 |
2020-04-16 |
ジェネンテック， インコーポレイテッド |
ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
|
|
US11707472B2
(en)
|
2017-06-05 |
2023-07-25 |
Viking Therapeutics, Inc. |
Compositions for the treatment of fibrosis
|
|
CA3075877A1
(en)
|
2017-09-14 |
2019-03-21 |
Riken |
Method for producing retinal tissues
|
|
WO2019079119A1
(en)
*
|
2017-10-17 |
2019-04-25 |
IFM Tre, Inc. |
SULFONAMIDES AND ASSOCIATED COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
|
|
CN109929806B
(zh)
|
2017-12-19 |
2020-05-08 |
北京吉源生物科技有限公司 |
一种表达glp1和fgf21的干细胞及其用途
|
|
AR114263A1
(es)
|
2018-02-26 |
2020-08-12 |
Genentech Inc |
Compuestos terapéuticos y métodos para utilizarlos
|
|
ES3053674T3
(en)
|
2018-03-22 |
2026-01-23 |
Viking Therapeutics Inc |
Crystalline forms and methods of producing crystalline forms of a compound
|
|
US10947251B2
(en)
|
2018-03-30 |
2021-03-16 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
|
TW202003490A
(zh)
|
2018-05-22 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
|
BR112021000139A2
(pt)
|
2018-07-19 |
2021-04-06 |
Astrazeneca Ab |
Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma
|
|
WO2020117962A1
(en)
|
2018-12-05 |
2020-06-11 |
Viking Therapeutics, Inc. |
Compositions for the treatment of fibrosis and inflammation
|
|
EP3894383A1
(en)
|
2018-12-12 |
2021-10-20 |
Autobahn Therapeutics, Inc. |
Novel thyromimetics
|
|
CA3130371A1
(en)
|
2019-03-01 |
2020-09-10 |
Autobahn Therapeutics, Inc. |
Novel thyromimetics
|
|
KR20210138639A
(ko)
|
2019-03-13 |
2021-11-19 |
다이니뽄 스미토모 세이야쿠 가부시키가이샤 |
이식용 신경 망막의 품질을 평가하는 방법 및 이식용 신경 망막 시트
|
|
US20220306630A1
(en)
*
|
2019-08-06 |
2022-09-29 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
KR20220121239A
(ko)
|
2019-11-29 |
2022-08-31 |
아우토반 쎄라퓨틱스, 인크. |
신규한 갑상선 호르몬 모방제
|
|
JP7813730B2
(ja)
|
2020-06-17 |
2026-02-13 |
オートバーン セラピューティクス，インク． |
甲状腺様作用剤
|
|
WO2021257851A1
(en)
|
2020-06-17 |
2021-12-23 |
Autobahn Therapeutics, Inc. |
Thyromimetics
|
|
EP4201428A4
(en)
|
2020-09-11 |
2024-09-11 |
Sumitomo Pharma Co., Ltd. |
MEDIUM FOR TISSUE INTENDED FOR TRANSPLANTATION
|
|
CA3194226A1
(en)
|
2020-09-11 |
2022-03-17 |
Riken |
Complex containing neural retina-containing cell aggregates and matrix, and method for manufacturing same
|
|
WO2023090427A1
(ja)
|
2021-11-19 |
2023-05-25 |
国立研究開発法人理化学研究所 |
シート状網膜組織の製造方法
|
|
US12377058B1
(en)
|
2024-04-29 |
2025-08-05 |
Imam Mohammad Ibn Saud Islamic University |
Method for inhibiting proliferation of cancer cells
|